Interview with Devaney Baccarin, VP & General Manager, Astellas Pharma…
In July 2011, Astellas celebrated its two-year anniversary in Brazil. However, we saw entry into Russia in 1992, China in 1994, and India in 2008. What was it about Brazil…
Address: Avenida das Nações Unidas, 14.171, Rochaverá Corporate Towers, Torre Marble – 3º andar, Cj. 302,Brazil
Tel: (55 11) 3027-4500
Web: http://www.astellasfarma.com.br/
In July 2009, Astellas Pharma Brazil (AFB) was created due to remarkable growth of the economy in the sector of health care. In April 2010, the Brazilian subsidiary started to promote and distribute products directly that were licensed to other companies.
In Brazil, specifically, Astellas is focused on three areas encompassed in the Astellas Group, Dermatology, Urology and Infectious Diseases. These are the foundations for growth and recognition of Astellas in the Brazilian pharmaceutical market.
Astellas Brazil focuses on becoming the leader in the Brazilian pharmaceutical industry, supports the company’s business philosophy, a VISION 2015, which seeks to become a ‘world leader in the category.’
Omnic®, Omnic OCAS®, Vesicare, Mycamine
In July 2011, Astellas celebrated its two-year anniversary in Brazil. However, we saw entry into Russia in 1992, China in 1994, and India in 2008. What was it about Brazil…
As Latin America’s largest pharma market, worth USD 62 billion in 2024, Brazil is retooling its industry to meet new demands. Driven by changing demographics, chronic disease burdens, and the…
Brazil’s pharmaceutical sector is undergoing a quiet but significant transformation. Once dominated by multinationals and focused largely on generics, a group of leading domestic players is now charting a different…
Dr. Rodrigues Mota brings two decades of leadership experience within ANVISA, the Brazilian Health Regulatory Authority, where he has held multiple senior positions and now serves as a key architect…
Some of the top recent stories out of Latin America’s dynamic pharmaceutical and healthcare market. In Mexico, President Claudia Sheinbaum announced new investments from four leading Mexican pharmas totalling USD…
After a globe-trotting career that led him to diverse global affiliates, the long-term Takeda executive Rodrigo Rodriguez is going full circle. Returning to where he began his career at the…
A roundup of the biggest stories from Brazil’s pharma industry, including Teuto’s cannabis manufacturing deal with MediPharm; Eurofarma’s AI-based epilepsy joint venture with SK Biopharmaceuticals; EMS’s increased stake in Hypera…
With the largest public healthcare system in the world, Latin America’s biggest pharma market, its leading regulatory body, and a huge and diverse population, Brazil is a strategic destination for…
For the second consecutive year, DIA Europe hosted a Latin America Town Hall, a panel discussion to foster collaboration and share updates from regulatory activities in Latin America and Europe,…
An overview of some of the biggest stories from Latin American pharma and healthcare, including Brazil’s rollout of dengue vaccines following a sharp increase in cases; the Brazilian regulatory agency…
A roundup of some of the latest stories from Latin American pharma and healthcare, including Sanfer’s acquisition of Columbia-based injectables manufacturer Vitalis; medicine shortages in Colombia, and Chile’s move towards…
Brazil’s ANVISA is commonly recognised as LatAm’s leading national medicines regulator and is defined by the Pan American Health Organization (PAHO) as a National Regulatory Authority of Regional Reference (NRAr) for medicines…
The latest pharma news from Brazil, including the partnership between Biophytis and Innovation Solutions Pharma; Merck’s 100 years in Brazil; Eurofarma’s USD 100 million biotech investment, and GSK’s green light…
See our Cookie Privacy Policy Here
